Britain and America have forged a key trade agreement that will keep zero tariffs on UK pharmaceutical shipments being sold in the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This move ensures that import taxes on these key goods will remain at nothing for a duration of 36 months.
This deal is in response to recent warnings to significantly raise tariffs on patented drug imports, with potential rates mentioned up to double the cost.
"This arrangement with the Britain reinforces the international landscape for new treatments and establishes much-needed equity to U.S.–U.K. drug exports," a statement said.
Economic Impact
Medicines are one of the the United Kingdom's largest goods shipped to the America, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value represented 17.4% of total UK exports in that period.
"This deal protects work, stimulates investment and facilitates the UK to emerge as a international leader for life sciences," a government official remarked.
Key British Pledges
The pact includes several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to double overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Previously, refunds were more than 20%.
Broader Context
The pact comes amid a long-running row between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were intensified by arguments that US consumers were paying a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been directed toward American operations.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the past decade.
